New Medicine Roflumilast Helps Psoriasis

New studies show that a medicine called roflumilast may help people with psoriasis. It can be taken by mouth or put on the skin. It helps make the skin better and is safe for most people.
By Newsroom | Health, Medicine |

Early Findings Indicate Effectiveness and Favorable Safety Profile for Skin Condition

Research into roflumilast, a medication targeting inflammation, is showing positive results for people with psoriasis. This chronic skin condition, marked by redness, thickening, and scaling, can greatly impact a person's quality of life. Studies suggest that roflumilast, whether taken by mouth or applied to the skin, may offer a helpful treatment option, with most patients tolerating it well and showing signs of improvement.

Context of Roflumilast Research for Psoriasis

Psoriasis is a long-term inflammatory skin disease that causes discomfort and visible changes to the skin, affecting many individuals' well-being. Historically, common treatments for plaque psoriasis include glucocorticoids and vitamin D derivatives. However, concerns about side effects like skin thinning highlight the ongoing need for safe and effective alternatives.

Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, works by reducing inflammation. This has led researchers to investigate its potential in treating psoriasis. Studies have looked at both oral (taken by mouth) and topical (applied to the skin) forms of the drug.

Read More: Plan to Lower Cigarette Prices to Fight Illegal Sales Faces Debate

Recent investigations have focused on the real-world effectiveness and safety of oral roflumilast. A study in Portugal tracked adults with moderate to severe plaque psoriasis who took oral roflumilast 500 mcg daily for 24 weeks. Another effort reviewed existing studies to analyze the benefits and risks of topical roflumilast. Results from a randomized controlled trial called PSORRO have also offered insights into how oral roflumilast affects patients' reported outcomes.

Evidence for Roflumilast's Benefit in Psoriasis

Evidence from multiple studies points towards roflumilast being a potentially beneficial treatment for psoriasis.

  • Systematic Review and Meta-Analysis (Topical Roflumilast): A review of randomized controlled trials for topical roflumilast found it to be effective in treating plaque psoriasis. While overall side effects were noted, there was no significant difference in treatment-related adverse events, serious adverse events, or events leading to discontinuation compared to the placebo group. The review assessed outcomes like the Investigator's Global Assessment (IGA) and Psoriasis Area and Severity Index (PASI) scores.

  • Real-World Study (Oral Roflumilast): A prospective cohort study in Portugal evaluated oral roflumilast in adults with moderate-to-severe plaque psoriasis. The findings suggest it demonstrated real-world effectiveness and a good safety profile over a 24-week period.

  • Systematic Review and Meta-Analysis (Oral Roflumilast): A pooled analysis from a systematic review indicated that roflumilast favored improved response rates compared to placebo in psoriasis treatment at various time points, based on Psoriasis Area and Severity Index (PASI) measures. This review also noted that roflumilast was generally well-tolerated across the studies examined.

  • Randomized Controlled Trial (Oral Roflumilast): Results from the PSORRO randomized controlled trial specifically looked at patient-reported outcomes with oral roflumilast for psoriasis, suggesting improvements in how patients feel their condition is managed.

  • Case Reports and Literature Review: Some reports have detailed long-term clearance of severe plaque psoriasis with oral roflumilast therapy. There's also mention of considerable improvement in related conditions like hidradenitis suppurativa.

Analysis of Roflumilast's Efficacy and Safety

The available data present a consistent picture of roflumilast's potential in managing psoriasis.

Efficacy Indicators

  • Improved Psoriasis Scores: Pooled analyses from systematic reviews favor roflumilast in improving Psoriasis Area and Severity Index (PASI) scores, a standard measure for assessing psoriasis severity.

  • Real-World Effectiveness: Studies tracking patients in everyday clinical settings suggest roflumilast delivers actual benefits for those with moderate-to-severe plaque psoriasis.

  • Patient-Reported Outcomes: Research, such as the PSORRO trial, is beginning to quantify improvements from the patient's perspective, indicating better overall well-being and symptom management.

Safety and Tolerability

  • Generally Well-Tolerated: Across multiple studies, roflumilast, both oral and topical, has been described as generally well-tolerated by patients.

  • No Increased Serious Adverse Events: For topical roflumilast, reviews found no difference in treatment-related adverse events, serious adverse events, or discontinuations due to side effects when compared to a placebo.

  • Considerations: While safety is largely positive, potential side effects remain a point of observation, underscoring the need for continued monitoring in clinical practice.

Discussion of Roflumilast's Role

The investigation into roflumilast for psoriasis centers on its anti-inflammatory properties. As a PDE4 inhibitor, it targets key pathways involved in the inflammatory processes that drive psoriasis.

Topical vs. Oral Administration

  • Topical Roflumilast: Research suggests topical application can be effective for plaque psoriasis, offering an alternative to established treatments and potentially mitigating some of their drawbacks, like skin atrophy.

  • Oral Roflumilast: Studies examining oral roflumilast indicate its effectiveness in real-world settings for moderate-to-severe plaque psoriasis. Its use has been associated with long-term clearance in some severe cases.

Emerging Evidence and Future Directions

The body of evidence suggests that roflumilast is a viable therapeutic option. Its efficacy in improving clinical scores and patient-reported outcomes, coupled with a generally favorable safety profile, positions it as a notable development. Further research, including broader real-world data collection and long-term follow-up studies, will continue to refine understanding of its optimal use and place in psoriasis management.

Conclusion and Implications

Current evidence indicates that roflumilast shows promise as a treatment for psoriasis, with both oral and topical formulations demonstrating effectiveness and a favorable safety profile in early research.

Read More: Weight Loss Drugs May Cause Scurvy, Doctors Say

  • Effectiveness: Pooled analyses and real-world studies suggest roflumilast can improve psoriasis severity, as measured by standard indices like PASI, and lead to better patient-reported outcomes.

  • Safety: Across various studies, roflumilast has been generally well-tolerated, with no significant increase in serious adverse events reported for the topical form.

  • Therapeutic Potential: Roflumilast's anti-inflammatory action makes it a valuable addition to the therapeutic arsenal for psoriasis, particularly for individuals with moderate-to-severe plaque psoriasis who may not respond adequately to or tolerate existing treatments.

The findings imply that roflumilast warrants consideration in clinical practice for psoriasis management. Continued observation and data gathering are essential to fully understand its long-term impact and best application.

Sources Used

Read More: Eating More Red Meat May Raise Diabetes Risk

Frequently Asked Questions

Q: What is roflumilast?
Roflumilast is a medicine that helps lower swelling in the body. It is being studied to treat skin problems like psoriasis.
Q: How does roflumilast help psoriasis?
Roflumilast works by reducing the body's swelling that causes psoriasis. It can help make red, scaly skin better.
Q: Is roflumilast safe to use?
Early studies show that roflumilast is safe for most people. It is usually well-tolerated, but some people may have side effects.
Q: Can roflumilast be taken by mouth or put on the skin?
Yes, studies have looked at both ways of using roflumilast. It can be taken as a pill or applied directly to the skin.
Q: What kind of psoriasis does roflumilast treat?
It is being studied for plaque psoriasis, which is a common type that causes red, raised patches on the skin.